about
Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humansMMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancerETS-targeted therapy: can it substitute for MEK inhibitors?Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityPotent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathwaysKRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glandsRIN1 is a breast tumor suppressor gene.Splice variants of SmgGDS control small GTPase prenylation and membrane localizationGene interaction enrichment and network analysis to identify dysregulated pathways and their interactions in complex diseasesExpression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma.Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancerCharacterization of KRAS rearrangements in metastatic prostate cancer.MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAFNRAS mutation causes a human autoimmune lymphoproliferative syndrome.Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferationAurora kinase targeting in lung cancer reduces KRAS-induced transformation.Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.RasV12-mediated down-regulation of CCAAT/enhancer binding protein beta in immortalized fibroblasts requires loss of p19Arf and facilitates bypass of oncogene-induced senescenceThe RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.Oncogene homologue Sch9 promotes age-dependent mutations by a superoxide and Rev1/Polzeta-dependent mechanism.Thinking outside the box about Ras.Isoform-specific ras functions in development and cancer.Clinicopathologic and molecular disease prognostication for papillary thyroid cancer.Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.Cancer therapy based on oncogene addiction.Aging, nutrient signaling, hematopoietic senescence, and cancer.Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype.Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation.Negative regulation of Shh levels by Kras and Fgfr2 during hair follicle developmentReversal of the Migratory and Invasive Phenotype of Ras-Transfected Mammary Cells by Photodynamic Therapy Treatment.Insulin/IGF-I and related signaling pathways regulate aging in nondividing cells: from yeast to the mammalian brain.Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition
P2860
Q24618226-BC67D9D0-A7D6-4422-8B41-9422D9405689Q28250940-CF9829CD-E534-4175-92BF-6325DBA5B96BQ33638827-F5A3C0BF-5C6C-47DF-A1E2-FF4694F81CC0Q33743847-68D0F19B-19ED-46E7-9F61-FA84333DCCF8Q33801421-BC9C3C7C-73E7-483F-9326-20C5144D88F0Q33858490-7AE28652-4B62-4ADF-8B67-59A54C98B1F2Q34105349-9B559D0E-FE96-4A64-9D0F-AD52F159AD8FQ34175671-EBE4B901-435A-4B2A-929F-BA99C60496D4Q34284968-C8499DEA-C47A-4873-96DD-6F6A9134904AQ34302997-C703C375-2FCF-4867-A991-BF242A945B20Q34485829-FAED8689-6294-4663-8DFC-85D0A7D8251FQ35076220-8C4738FC-7783-4B05-BC09-E82D999F13C4Q35581673-BE4D2F0F-6A84-45D8-B23A-843C212487D7Q35606229-BB8D7A62-1A3C-45DA-AA7E-8F028FA2E151Q35829141-A40FFB90-CC16-4C76-9F5B-75BD308B7CCDQ35857112-DF5145C8-4C74-4574-8237-89CA6ECC96E2Q36538710-1A2F5ACB-91B8-4E7F-B32C-AA7C9DFC61FFQ37038356-DD5807B7-2038-48CD-9D7C-D77781B37901Q37109358-65B22B02-6637-4072-821E-65F36AFC9E37Q37219345-8BDD13B3-F745-4FD6-8D52-3FEB8DD565D4Q37290440-6464B382-73B5-47C6-A9FA-AAD275970959Q37301884-101BB294-6008-4810-812B-82DB7C6EA90BQ37323159-BFBC82AB-2D36-4058-88C2-47BD711D22BCQ37353436-5CEAB8CE-07C9-4A98-95FD-35700C42A0BEQ37401355-8401AED5-18FB-4BA8-BDEA-2A5A5EF765CBQ37598938-ABB1949A-5004-4401-9EE7-389C8FEB207BQ37825724-B28C0BB8-D05C-4723-B56D-7168CD6E92ABQ37863612-B26B545E-3935-462D-8549-104BA586BCE7Q38191999-33C9188E-6279-4DA8-9693-11DEB42C423FQ38233105-0EA32FE7-FA6C-4B84-AB40-684EB6270069Q38812141-27D08AD1-2895-4867-9837-4688DDCEC384Q39979160-E2E5C3B5-F19C-448D-AEB5-2A2E7E134FABQ41761816-168A072B-ED4E-44EF-83E5-F21377933D6BQ42136008-69DA81C8-7B21-4844-9855-846A26E403F7Q51628923-6390E175-0B09-4F1A-AB5B-C069D58EC803Q53346541-05F0D73D-2E01-4433-B86C-1D0649CD6C24Q56942104-71932698-27B0-4001-8352-FA8BA121794E
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cancer targets in the Ras pathway.
@ast
Cancer targets in the Ras pathway.
@en
type
label
Cancer targets in the Ras pathway.
@ast
Cancer targets in the Ras pathway.
@en
prefLabel
Cancer targets in the Ras pathway.
@ast
Cancer targets in the Ras pathway.
@en
P2093
P2860
P356
P1476
Cancer targets in the Ras pathway.
@en
P2093
P2860
P304
P356
10.1101/SQB.2005.70.044
P577
2005-01-01T00:00:00Z